Advertisement

Using FDG-PET to guide targeted cardiac magnetic resonance imaging in patients with suspected cardiac sarcoidosis

  • Madison B. Sharp
  • Aaron Soufer
  • Medhat Abdelmessih
  • Lynda E. Rosenfeld
  • Lauren A. Baldassarre
  • Edward J. MillerEmail author
Images that Teach

Notes

Disclosure

Dr. Miller has research funding from Bracco, Inc for FDG/Rb-82 PET perfusion imaging in CS, unrelated to the current study, as well as consulting for Bracco, Pfizer, GE, and Alnylam. The remaining authors have no funding to report. Dr. Rosenfeld has received Fellowship Support from: Abbott, Boston Scientific and Medtronic. The remaining authors have declared that no competing interests exist.

References

  1. 1.
    Blankstein R, Waller AH. Evaluation of known or suspected cardiac sarcoidosis. Circ Cardiovasc Imaging 2016;9:e000867.CrossRefGoogle Scholar
  2. 2.
    Wada K, Niitsuma T, Yamaki T, Masuda A, Ito H, Kubo H, et al. Simultaneous cardiac imaging to detect inflammation and scar tissue with 18F-fluorodeoxyglucose in cardiac sarcoidosis. J Nucl Cardiol 2016;23:1180-2.CrossRefGoogle Scholar
  3. 3.
    Ohira H, Birnie DH, Pena E, et al. Comparison of 18F-fluorodeoxyglucose positron emission tomography (FDG PET) and cardiac magnetic resonance (CMR) in corticosteroid-naive patients with conduction system disease due to cardiac sarcoidosis. Eur J Nucl Med Mol Imaging 2016;43:259-69.CrossRefGoogle Scholar

Copyright information

© American Society of Nuclear Cardiology 2019

Authors and Affiliations

  • Madison B. Sharp
    • 1
  • Aaron Soufer
    • 1
  • Medhat Abdelmessih
    • 1
  • Lynda E. Rosenfeld
    • 1
  • Lauren A. Baldassarre
    • 1
  • Edward J. Miller
    • 1
    Email author
  1. 1.Section of Cardiovascular MedicineYale School of MedicineNew HavenUSA

Personalised recommendations